

Drugs and Aging, 2019

Supplement: Safety of Anti-Osteoarthritis Medications

Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: Outcomes of a systematic review and meta-analysis

Germain Honvo, Victoria Leclercq, Anton Geerinck, Thierry Thomas, Nicola Veronese, Alexia Charles, Véronique Rabenda, Charlotte Beaudart, Cyrus Cooper, Jean-Yves Reginster, Olivier Bruyère

ELECTRONIC SUPPLEMENTARY MATERIAL 2

A) All topical NSAIDs

Figure 7: Forest plot displaying the result of the meta-analysis comparing skin and subcutaneous tissue disorders with all topical nonsteroidal anti-inflammatory drugs (NSAIDs) versus placebo in patients with osteoarthritis (OA).




Figure 8: Forest plot displaying the result of the meta-analysis comparing cardiac disorders with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.




Figure 9: Forest plot displaying the result of the meta-analysis comparing vascular disorders with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.




Figure 10: Forest plot displaying the result of the meta-analysis comparing nervous system disorders with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.




Figure 11: Forest plot displaying the result of the meta-analysis comparing musculoskeletal and connective tissue disorders with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.




Figure 12: Forest plot displaying the result of the meta-analysis comparing severe adverse events with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.




Figure 13: Forest plot displaying the result of the meta-analysis comparing serious adverse events with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.




Figure 14: Forest plot displaying the result of the meta-analysis comparing dropouts due to adverse events with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.





Figure 15: Forest plot displaying the result of the meta-analysis comparing total adverse events (AEs) (any AEs) with all topical nonsteroidal anti-inflammatory drugs versus placebo in patients with OA.



B) Topical diclofenac

Figure 16: Forest plot displaying the result of the meta-analysis comparing skin and subcutaneous tissue disorders with topical diclofenac versus placebo in patients with OA.




Figure 17: Forest plot displaying the result of the meta-analysis comparing cardiac disorders with topical diclofenac versus placebo in patients with OA.




Figure 18: Forest plot displaying the result of the meta-analysis comparing vascular disorders with topical diclofenac versus placebo in patients with OA.




Figure 19: Forest plot displaying the result of the meta-analysis comparing nervous system disorders with topical diclofenac versus placebo in patients with OA.




Figure 20: Forest plot displaying the result of the meta-analysis comparing musculoskeletal and connective tissue disorders with topical diclofenac versus placebo in patients with OA.




Figure 21: Forest plot displaying the result of the meta-analysis comparing severe adverse events with topical diclofenac versus placebo in patients with OA.




Figure 22: Forest plot displaying the result of the meta-analysis comparing serious adverse events with topical diclofenac versus placebo in patients with OA.




Figure 23: Forest plot displaying the result of the meta-analysis comparing dropouts due to adverse events with topical diclofenac versus placebo in patients with OA.





Figure 24: Forest plot displaying the result of the meta-analysis comparing total adverse events (Any AEs) with topical diclofenac versus placebo in patients with OA.



C) Topical ketoprofen

Figure 25: Forest plot displaying the result of the meta-analysis comparing skin and subcutaneous tissue disorders with topical ketoprofen versus placebo in patients with OA.




Figure 26: Forest plot displaying the result of the meta-analysis comparing gastrointestinal disorders with topical ketoprofen versus placebo in patients with OA.




Figure 27: Forest plot displaying the result of the meta-analysis comparing cardiac disorders with topical ketoprofen versus placebo in patients with OA.




Figure 28: Forest plot displaying the result of the meta-analysis comparing vascular disorders with topical ketoprofen versus placebo in patients with OA.




Figure 29: Forest plot displaying the result of the meta-analysis comparing nervous system disorders with topical ketoprofen versus placebo in patients with OA.





Figure 30: Forest plot displaying the result of the meta-analysis comparing musculoskeletal and connective tissue disorders with topical ketoprofen versus placebo in patients with OA.



Ketoprofen: Severe adverse events (meta-analysis not possible, since zero events reported by all included studies, both in the intervention and placebo groups)

Figure 31: Forest plot displaying the result of the meta-analysis comparing serious adverse events with topical ketoprofen versus placebo in patients with OA.




Figure 32: Forest plot displaying the result of the meta-analysis comparing dropouts due to adverse events with topical ketoprofen versus placebo in patients with OA.






Figure 33: Forest plot displaying the result of the meta-analysis comparing total adverse events (Any AEs) with topical ketoprofen versus placebo in patients with OA.




D) Ibuprofen

Figure 34: Forest plot displaying the result of the meta-analysis comparing skin and subcutaneous tissue disorders with topical ibuprofen versus placebo in patients with OA.



Ibuprofen: for gastrointestinal disorders, cardiac disorders, vascular disorders, nervous system disorders, musculoskeletal and connective tissue disorders, zero adverse events were reported in both the intervention and placebo groups.

Figure 35: Forest plot displaying the result of the meta-analysis comparing severe adverse events with topical ibuprofen versus placebo in patients with OA.



Ibuprofen: zero serious adverse events were reported in both the intervention and placebo groups.

Figure 36: Forest plot displaying the result of the meta-analysis comparing dropouts due to adverse events with topical ibuprofen versus placebo in patients with OA.




Figure 37: Forest plot displaying the result of the meta-analysis comparing total adverse events (Any AEs) with topical ibuprofen versus placebo in patients with OA.

